CLINICAL_TRIALS
trial_result
· 2014-06-18
Clinical Trial Update: Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes [Phase 2]
Summary
Phase 2 study of ramucirumab (Cyramza) assesses QTc interval changes; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Cancer, Solid Tumor | Phase 2 | Status: COMPLETED | Results posted: 2014-06-18